首页> 外文期刊>Cell cycle >Erratum: Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment (Cell Cycle (2012) 12:12 (3837-3850))
【24h】

Erratum: Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment (Cell Cycle (2012) 12:12 (3837-3850))

机译:勘误:评估候选生物标记以预测癌细胞对PARP-1抑制剂治疗的敏感性或耐药性(Cell Cycle(2012)12:12(3837-3850))

获取原文
获取原文并翻译 | 示例
       

摘要

It has come to the attention of the authors that in their Report, "Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment," in the October 15, 2012 issue of Cell Cycle, an important source of funding was omitted. Dr M. Mistrik was supported by the GACR grant no. 301/11/P554.
机译:引起作者注意的是,他们的报告“重要的候选生物标志物的评估,以预测癌细胞对PARP-1抑制剂治疗的敏感性或耐药性”(2012年10月15日,《细胞周期》)被省略了。 M. Mistrik博士得到了GACR的资助。 301/11 / P554。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号